A study published in Lancet Hematology showed promising results for using eltrombopag and cyclosporin A as first-line treatment for severe aplastic anemia. The multicenter phase 2 trial treated 54 patients with severe AA and found a 6-month hematologic overall response rate of 46%, with a complete response rate of 4%. The most common adverse events were increased bilirubin, nausea, increased liver enzyme levels, and diarrhea. The authors concluded that this combination therapy was effective and safe for treating severe AA. The study was supported by Novartis Pharmaceuticals. Further details can be found in the original publication on Hematology Advisor.
Source link
Eltrombopag Plus Cyclosporin A Show Activity as First-Line Treatment of Aplastic Anemia
